Switch theme
Sign up to access all valuation multiples
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
2006
8
Last FY Revenue n/a
Last FY EBITDA -$16.0M
$129M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Greenwich LifeSciences achieved revenue of n/a and an EBITDA of -$16.0M.
Greenwich LifeSciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Greenwich LifeSciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$16.0M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$14.7M | XXX | -$16.0M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$14.6M | XXX | -$15.8M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Greenwich LifeSciences's stock price is $10.
Greenwich LifeSciences has current market cap of $132M, and EV of $129M.
See Greenwich LifeSciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $129M | $132M | XXX | XXX | XXX | XXX | $-1.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Greenwich LifeSciences has market cap of $132M and EV of $129M.
Greenwich LifeSciences's trades at n/a EV/Revenue multiple, and -8.1x EV/EBITDA.
Equity research analysts estimate Greenwich LifeSciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Greenwich LifeSciences has a P/E ratio of -9.0x.
See valuation multiples for Greenwich LifeSciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $132M | XXX | $132M | XXX | XXX | XXX |
| EV (current) | $129M | XXX | $129M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -8.1x | XXX | XXX | XXX |
| EV/EBIT | -8.8x | XXX | -8.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.0x | XXX | -8.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -17.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGreenwich LifeSciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.0M for the same period.
Greenwich LifeSciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Greenwich LifeSciences's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Greenwich LifeSciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Greenwich LifeSciences acquired XXX companies to date.
Last acquisition by Greenwich LifeSciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Greenwich LifeSciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Greenwich LifeSciences founded? | Greenwich LifeSciences was founded in 2006. |
| Where is Greenwich LifeSciences headquartered? | Greenwich LifeSciences is headquartered in United States of America. |
| How many employees does Greenwich LifeSciences have? | As of today, Greenwich LifeSciences has 8 employees. |
| Who is the CEO of Greenwich LifeSciences? | Greenwich LifeSciences's CEO is Mr. Snehal S. Patel. |
| Is Greenwich LifeSciences publicy listed? | Yes, Greenwich LifeSciences is a public company listed on NAS. |
| What is the stock symbol of Greenwich LifeSciences? | Greenwich LifeSciences trades under GLSI ticker. |
| When did Greenwich LifeSciences go public? | Greenwich LifeSciences went public in 2020. |
| Who are competitors of Greenwich LifeSciences? | Similar companies to Greenwich LifeSciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Greenwich LifeSciences? | Greenwich LifeSciences's current market cap is $132M |
| Is Greenwich LifeSciences profitable? | Yes, Greenwich LifeSciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
